1. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimesions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.

2. Carroll D, Tramèr M, McQuay H, Nye B, Moore A. Randomization is important in studies with pain outcomes: systematic review of transcutneous electrical nerve stimulation in acute postoperative pain. Br J Anaesth 1996; 77: 798-803.

3. Ernst E, White AR. Acupuncture for back pain: a meta-analysis of randomised controlled trials. Arch Intern Med 1998; 158: 2235-2241.

4. Li Wan Po A. A practical guide to undertaking a systematic review. Pharmaceut J 1997; 258: 518-520.

5. Bell RF, Dahl JB, Moore RA, Kalso E. Peri-operative keta-mine for acute postoperative pain. A quantitative and qualitative systematic review (Cochrane review). Acta Anaesthesiol Scand 2005; 49: 1405-1428.

6. Moore A, Collins S, Carroll D, McQuay H. Paracetamol with and without codeine in acute pain: a quantitative systematic review. Pain 1997; 70: 193-201.

7. Edwards JE, McQuay HJ, Moore RA. Combination analgesic efficacy: individual patient data meta-analysis of single-dose oral tramadol plus acetaminophen in acute postoperative pain. J Pain Symptom Manage 2002; 23(2):121-30.

8. Moore RA, Gavaghan D, Tramèr, MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998; 78: 209-216.

9. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987; 107: 224-233.

10. Ezzo I, Berman B, Hadhazy VA, Jadad AR, Lao L, Singh BB. Is acupuncture effective for the treatment of chronic pain? A systematic review. Pain 2000; 86: 217-225.

11. Kalso E, Smith L, McQuay HJ, Moore RA. No pain, no gain: clinical excellence and scientific rigour - lessons learned from IA morphine. Pain 2002; 98: 269-275.

12. Antczak AA, Tang J, Chalmers TC. Quality assessment of randomized controlled trials in dental research. I. Methods. J Peridental Res 1986; 21: 305-314.

13. van Tulder MW, Assendelft WJ, Koes BW, et al. Method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group for Spinal Disorders. Spine 1997; 22: 2323-2330.

14. Oxman AD, Guyatt GH. Guidelines for reading literature reviews. Can Med Assoc J 1988; 138: 697-703.

15. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996; 276: 637-639.

16. Moher D, Schulz KF, Altman DG, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group ran-somised trials. Lancet 2001; 357: 1191-1194.

17. Campbell MK, Elbourne DR, Altman DG, for the CONSORT Group. CONSORT statement: extension to cluster randomised trials. BMJ 2004; 328: 702-708.

18. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW, for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295: 1152-1160.

19. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, for the CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med 2006; 144: 364-367.

20. Boutron I, Moher D, Altman DG, Schulz K, Ravaud P, for the CONSORT Group. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: an explanation and elaboration. Ann Intern Med 2008; 148: 295-309.

21. Hopewell S, Altman DG, Moher D, Schulz KF. Endorsement of the CONSORT Statement by high impact factor medical journal: a survey of journal editors and journal "Instructions to Authors". Trials 2008; 9: 1-7.

22. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUORUM statement. Quality of Reporting Meta-analyses. Lancet 1999; 354: 1896-1990.

23. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA 1998; 279: 1200-1205.

24. Wester K, Jonsson AK, Spigset O, Druid H, Hagg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 2008; 65: 573-579.

25. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. JAMA 1995; 274: 29-34.

26. Moore RA, Phillips CJ. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 1999; 2: 45-55.

27. Edwards JE, McQuay HJ, Moore RA, Collins SL. Reporting of adverse effects in clinical trials should be improved. Lessons from acute postoperative pain. J Pain Symptom Manage 1999; 81: 289-297.

28. Ioannidis JPA, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437-443.

29. Moore RA, McQuay HJ. Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. Pain 1997; 69: 287-294.

30. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078-1088.

31. Hernandez-Diaz S, Rodridguez LAG. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Arch Intern Med 2000; 160: 2093-2099.

32. Henry D, Page J, Whyte I, et al. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Clin Pharmacol 1997; 44: 85-90.

33. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Intern Med 2000; 160: 777-784.

34. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528.

35. Silverstein FE, Faich G, Golstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-i nflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomised controlled trial. JAMA 2000; 284: 1247-1255.

36. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-1933.

37. Bensen WG, Zhao SZ, Burke T, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000; 27: 1876-1883.

38. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000; 85: 169-182.

39. Ioannidis JP, Evans SJ, Gotzsche PC, et al. for the CONSORT Group. Better reporting of harms in randomized trials. An extension of the CONSORT statement. Ann Intern Med 2004; 141: 781-788.

40. Kalso E. Five easy pieces on evidence-based medicine (1): Introduction. Eur J Pain 2000; 4: 217-219.

41. Kalso E, Moore RA. Five easy pieces on evidence-based medicine (2): Why randomized and (placebo) controlled? Eur J Pain 2000; 4: 321-324.

42. Kalso E, Edwards J, McQuay HJ, Moore RA. Five easy pieces on evidence-based medicine (3): Quantitative systematic reviews. Eur J Pain 2001; 5: 227-230.

43. Kalso E, Edwards J, McQuay HJ, Moore RA. Five easy pieces on evidence-based medicine (4): Qualitative systematic reviews. Eur J Pain 2002; 6: 89-93.

44. Kalso E, Edwards J, McQuay HJ, Moore RA. Five easy pieces on evidence-based medicine (5): trading benefit against harm -pain relief vs. adverse effects. Eur J Pain 2002; 6: 409-412.

45. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.

46. Smith LA, Oldman AD, McQuay HJ, Moore RA. Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain. Pain 2000; 86: 119-132.


Natural Pain Management

Natural Pain Management

Do You Suffer From Chronic Pain? Do You Feel Like You Might Be Addicted to Pain Killers For Life? Are You Trapped on a Merry-Go-Round of Escalating Pain Tolerance That Might Eventually Mean That No Pain Killer Treats Your Condition Anymore? Have you been prescribed pain killers with dangerous side effects?

Get My Free Ebook

Post a comment